Talia Golan, MD, of the Oncology Institute, Sheba Medical Center, discusses phase III results from the POLO trial, which explored the question of whether maintenance olaparib could improve overall and progression-free survival for patients with germline BRCA-mutated metastatic pancreatic cancer (Abstract 378).
Richard S. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall survival seen in a front-line phase III study in advanced hepatocellular carcinoma, confirming this combination as the standard of care for patients with previously untreated, unresectable disease (Abstract 267).
Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quality of life when pembrolizumab was added to chemotherapy in patients with metastatic and unresectable esophageal cancers (Abstract 168).
Romain Cohen, MD, PhD, of the Mayo Clinic and Sorbonne University, discusses a post-hoc analysis of phase III results from the CALGB/SWOG 80702 study, which showed that adding the number of tumor deposits, a negative prognostic factor, to the count of lymph node metastases may improve the accuracy of TNM staging (Abstract 10).
Kai-Keen Shiu, MD, PhD, of the University College Hospital NHS Foundation Trust - London, discusses an interim analysis of PFS 2 results (defined as time from random assignment to progression on the next line of therapy or death) from the phase III KEYNOTE-177 trial. This study has already shown that first-line pembrolizumab provides a clinically meaningful and statistically significant improvement in PFS compared with chemotherapy in patients with microsatellite instability–high metastatic colorectal cancer (Abstract 6).
Rutika Mehta, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the 3-year regression-free and overall survival results from the JACCRO study, which compared the efficacy of S-1, an oral prodrug of fluorouracil, vs S-1 plus docetaxel after curative resection of stage III gastric cancer (Abstract 159).
